# Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

> **NCT02079740** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 96 (actual)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Navitoclax
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02079740
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-03-26
- **Primary completion:** 2022-12-01
- **Final completion:** 2027-03-09
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079740, "Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02079740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*